Model based on ultrasound and clinicopathological characteristics for early prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer

基于超声和临床病理特征的乳腺癌新辅助化疗病理完全缓解早期预测模型

阅读:1

Abstract

BACKGROUND: Accurate assessment of pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in breast cancer (BC) is crucial for mitigating chemotherapy-related toxicity in patients who do not respond to the treatment. Conventional ultrasound (US) has become a pivotal method for evaluating treatment response due to its cost-effectiveness, convenience, and absence of ionizing radiation. The objective of this study was to develop a model combining US and clinicopathological characteristics at baseline, as well as US features after one cycle of NAC, to predict the pCR to NAC in BC. METHODS: This retrospective study included 74 patients with invasive BC who underwent NAC from January 2022 to December 2023. Data from US and clinicopathological characteristics before NAC (pre-NAC) and US features after one cycle of NAC were collected from all patients. Univariate and multivariate analyses were used to screen the factors independently associated with pCR and to develop the prediction model. Receiver operating characteristic (ROC) curve analysis was performed, and the area under the curve (AUC), sensitivity, and specificity were calculated to assess the predictive efficiency. RESULTS: Four characteristics, including human epidermal growth factor receptor 2 (HER2)-positive [odds ratio (OR) 9.265; 95% confidence interval (CI): 1.617-53.095, P=0.012] and absence of posterior feature or posterior acoustic enhancement of the breast mass on the US pre-NAC (OR 9.435; 95% CI: 1.585-56.180, P=0.014), the maximum diameter reduction measured with the US (OR 1.081; 95% CI: 1.009-1.157, P=0.026), and the angular or spiculated margin of the breast lesion with the US after one cycle of NAC (OR 9.475; 95% CI: 1.247-71.969, P=0.030), were screened as independent predictors. The AUC, sensitivity, and specificity of the prediction model were 0.912, 90.0%, and 79.6%, respectively. CONCLUSIONS: US and clinicopathological characteristics at baseline and the US features after one cycle of NAC helped predict pCR for BC. The prediction model may enable early evaluation of the efficacy of treatment strategies and guide less invasive surgical options or personalized post-treatment plans.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。